U.S. markets closed
  • S&P Futures

    3,837.25
    +9.25 (+0.24%)
     
  • Dow Futures

    31,411.00
    +40.00 (+0.13%)
     
  • Nasdaq Futures

    12,830.75
    -1.00 (-0.01%)
     
  • Russell 2000 Futures

    2,191.60
    -8.40 (-0.38%)
     
  • Crude Oil

    63.16
    -0.37 (-0.58%)
     
  • Gold

    1,771.70
    -3.70 (-0.21%)
     
  • Silver

    27.43
    -0.25 (-0.90%)
     
  • EUR/USD

    1.2177
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.4014
    +0.0001 (+0.01%)
     
  • USD/JPY

    105.9480
    -0.2820 (-0.27%)
     
  • BTC-USD

    47,447.98
    -3,118.69 (-6.17%)
     
  • CMC Crypto 200

    944.09
    -50.57 (-5.08%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,446.17
    -722.10 (-2.39%)
     

Recap: Esperion Therapeutics Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Esperion Therapeutics (NASDAQ:ESPR) decreased after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 72.12% over the past year to ($3.89), which missed the estimate of ($3.76).

Revenue of $9,638,000 up by 881.47% year over year, which missed the estimate of $12,520,000.

Looking Ahead

Esperion Therapeutics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Feb 23, 2021

View more earnings on ESPR

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/h9ugsf9y

Technicals

Company's 52-week high was at $70.43

52-week low: $23.90

Price action over last quarter: Up 15.70%

Company Profile

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.